Two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag into registrational testing in one of the most important oncology disease areas—first-line non-small cell lung cancer (NSCLC).
What does everyone think of this?
Bristol Myers Lag-3 drug into phase 3 trials in first-line lung cancer field
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.3¢ |
Change
0.003(1.09%) |
Mkt cap ! $337.6M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.0¢ | 23.0¢ | $37.16K | 159.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 431542 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 268565 | 18 |
View Market Depth
| Last trade - 10.19am 10/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |